Illumina to divest cancer test maker Grail

Illumina to divest cancer test maker Grail after antitrust battles | Reuters

Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and ...

FTC Orders Illumina to Divest Cancer Detection Test Maker GRAIL ...

Illumina has an enormous financial incentive to ensure that GRAIL wins the innovation race in the U.S. MCED market. Illumina stands to earn ...

Statement Regarding Illumina's Decision to Divest Grail

Illumina, Inc. announced it would divest Grail, Inc. following a U.S. Court of Appeals for the Fifth Circuit decision that supported the ...

Illumina Announces Decision to Divest GRAIL

Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party sale or capital markets ...

Roundup: Illumina's long goodbye to cancer test maker Grail

Illumina took a bold step in 2021 when it closed the $8 billion acquisition of Grail, maker of a multi-cancer early detection test, before securing the ...

EC Approves Illumina's Plan to Divest Cancer Diagnostics Maker Grail

... cancer detection tests. Illumina's divestment plan sets out a timely path towards Grail's independence by ensuring it continues to be a ...

Illumina completes the divestiture of GRAIL

GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early ...

Illumina to Shed Cancer-Test Maker Grail After Antitrust Battle - WSJ

The gene-sequencing company said its goal was to complete the divestiture by the middle of 2024 · What to Read Next.

Grail spinoff by Illumina should end disastrous merger attempt | STAT

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening ...

Illumina to sell cancer-test maker Grail after latest antitrust ruling

, which makes gene-sequencing products, said it will divest Grail and will not appeal the court's decision. In October, European regulators had ...

Illumina to divest cancer test maker Grail if it loses US or EU court ...

Illumina Inc said on Wednesday it will divest cancer test maker Grail as expeditiously as possible if the life sciences company loses either ...

Illumina to divest cancer test maker Grail - New York Post

Grail, valued at $7.1 billion under Illumina's deal, is seeking to market a blood test that can diagnose many kinds of cancer, known as a liquid ...

Illumina's Antitrust Battles to End With Divestiture of Cancer Test ...

Illumina's Antitrust Battles to End With Divestiture of Cancer Test Maker Grail. Illumina has decided against further appeals of U.S. and ...

Illumina to part with Grail, ending battle with regulators | MedTech Dive

DNA sequencing company Illumina said Sunday it will divest Grail, the liquid biopsy maker ... blood samples drawn for MCED tests. Earlier ...

UPDATE 2-EU approves Illumina's plan to divest cancer test maker ...

U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust ...

EU Approves Illumina's Plan to Divest Cancer Test Maker Grail

EU Approves Illumina's Plan to Divest Cancer Test Maker Grail ... BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest ...

Genetic sequencing company Illumina to divest cancer ... - Axios

Genetic sequencing giant Illumina will finally divest cancer diagnostic test maker Grail after two years of battling with antitrust regulators.

FTC Orders Illumina to Divest GRAIL - Maryland Carey Law

The FTC ordered Illumina, a DNA sequencing provider, to divest GRAIL, a cancer detection test developer, to ensure that the race to develop and bring to market ...

GRAIL Statement on Divestiture

On December 17, 2023, Illumina announced it will divest GRAIL ... cancer early detection. Next year will be transformative for GRAIL ...

Illumina board approves Grail spinoff - BioPharma Dive

... cancer blood test maker will regain its independence. Illumina agreed to divest the business it bought for $8 billion in 2021 after facing ...